{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:45:42Z","timestamp":1791654342769,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","obstetanesthesia.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Obstetric Anesthesia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijoa.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T23:26:21Z","timestamp":1549841181000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery"],"prefix":"10.1016","volume":"39","author":[{"given":"R.","family":"Landau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijoa.2019.01.011_b0005","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy","volume":"130","author":"Committee on Obstetric","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4070","article-title":"Committee on substance use and prevention. A public health response to opioid use in pregnancy","volume":"139","author":"Patrick","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijoa.2019.01.011_b0015","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMra1600879","article-title":"Neonatal abstinence syndrome","volume":"375","author":"McQueen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0020","article-title":"Incidence of neonatal abstinence syndrome triples in US","volume":"354","author":"McCarthy","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijoa.2019.01.011_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/AOG.0000000000002054","volume":"130","author":"Reddy","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0030","unstructured":"Available at: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2017-cdc-drug-surveillance-report.pdf. Accessed December, 2018."},{"key":"10.1016\/j.ijoa.2019.01.011_b0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ajo.12823","article-title":"Prescription opioid use in pregnancy","volume":"58","author":"Blandthorn","year":"2018","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0040","unstructured":"Available at: https:\/\/www.psychiatry.org\/psychiatrists\/practice\/dsm. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Accessed December, 2018."},{"key":"10.1016\/j.ijoa.2019.01.011_b0045","unstructured":"Available at: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pregnancy_opioid_pain_factsheet-a.pdf. Accessed December, 2018."},{"key":"10.1016\/j.ijoa.2019.01.011_b0050","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/ALN.0000000000000472","article-title":"Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes","volume":"121","author":"Maeda","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0055","first-page":"5","article-title":"Birth and neonatal outcomes following opioid use in pregnancy: a Danish Population-Based Study","volume":"9","author":"Norgaard","year":"2015","journal-title":"Subst Abuse"},{"key":"10.1016\/j.ijoa.2019.01.011_b0060","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization \u2013 United States, 1999\u20132014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijoa.2019.01.011_b0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jnma.2017.04.002","article-title":"Opioid utilization by pregnant women with sickle cell disease and the risk of neonatal abstinence syndrome","volume":"110","author":"Nnoli","year":"2018","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.ijoa.2019.01.011_b0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1213\/ANE.0000000000002718","article-title":"Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies","volume":"127","author":"Aiyer","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijoa.2019.01.011_b0075","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/AOG.0000000000002562","article-title":"Opioid detoxification during pregnancy: a systematic review","volume":"131","author":"Terplan","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0080","unstructured":"Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm600092.htm. Accessed December, 2018."},{"key":"10.1016\/j.ijoa.2019.01.011_b0085","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/phar.1958","article-title":"Methadone, Buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women","volume":"37","author":"Tran","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijoa.2019.01.011_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogc.2017.04.028","article-title":"349-Substance use in pregnancy","volume":"39","author":"Ordean","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ijoa.2019.01.011_b0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.whi.2017.10.011","article-title":"Federal and State policy efforts to address maternal opioid misuse: gaps and challenges","volume":"28","author":"Saunders","year":"2018","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.ijoa.2019.01.011_b0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.addbeh.2018.05.016","article-title":"The pregnancy recovery center: a women-centered treatment program for pregnant and postpartum women with opioid use disorder","volume":"86","author":"Krans","year":"2018","journal-title":"Addict Behav"},{"key":"10.1016\/j.ijoa.2019.01.011_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsat.2018.04.003","article-title":"Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States","volume":"89","author":"Short","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.ijoa.2019.01.011_b0110","first-page":"1","article-title":"Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian States","volume":"9","author":"Patrick","year":"2018","journal-title":"Subst Abuse"},{"key":"10.1016\/j.ijoa.2019.01.011_b0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/00952990.2015.1047502","article-title":"Opioid use disorder during pregnancy in Tennessee: expediency vs. science","volume":"41","author":"Martin","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.ijoa.2019.01.011_b0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ADM.0000000000000398","article-title":"The use of serum methadone\/metabolite ratios to monitor changing perinatal pharmacokinetics","volume":"12","author":"McCarthy","year":"2018","journal-title":"J Addict Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ADM.0b013e31815ca2c6","article-title":"Dosing adjustments in postpartum patients maintained on buprenorphine or methadone","volume":"2","author":"Jones","year":"2008","journal-title":"J Addict Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jsat.2014.04.004","article-title":"Postpartum changes in methadone maintenance dose","volume":"47","author":"Pace","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.ijoa.2019.01.011_b0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ijoa.2019.01.011_b0140","doi-asserted-by":"crossref","first-page":"e1013","DOI":"10.4088\/JCP.16m11318","article-title":"Corrected QT interval and methadone dose and concentrations in pregnant and postpartum women","volume":"78","author":"Bogen","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ijoa.2019.01.011_b0145","first-page":"380","article-title":"Dosing and monitoring of methadone in pregnancy: literature review","volume":"65","author":"Shiu","year":"2012","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.ijoa.2019.01.011_b0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ogc.2018.05.001","article-title":"Treatment of perinatal opioid use disorder","volume":"45","author":"Boyars","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.ijoa.2019.01.011_b0155","first-page":"1","article-title":"Transdermal buprenorphine for moderate chronic noncancer pain syndromes","author":"Pergolizzi","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ijoa.2019.01.011_b0160","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/bcp.13642","article-title":"Gestational changes in buprenorphine exposure: a physiologically-based pharmacokinetic analysis","volume":"84","author":"Zhang","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"64","key":"10.1016\/j.ijoa.2019.01.011_b0165","article-title":"Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy","volume":"216","author":"Bastian","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"459","key":"10.1016\/j.ijoa.2019.01.011_b0170","article-title":"An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy","volume":"217","author":"Caritis","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0175","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ijoa.2019.01.011_b0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1360-0443.2012.04036.x","article-title":"Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues and lessons learned","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","article-title":"Buprenorphine and naloxone compared with methadone treatment in pregnancy","volume":"125","author":"Wiegand","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/add.13462","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child","volume":"111","author":"Zedler","year":"2016","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1016\/j.ijoa.2019.01.011_b0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1016\/j.ijoa.2019.01.011_b0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1360-0443.2012.04039.x","article-title":"Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates","volume":"107","author":"Gaalema","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.drugalcdep.2013.06.004","article-title":"Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone","volume":"133","author":"Gaalema","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ijoa.2019.01.011_b0210","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1056\/NEJMoa1614835","article-title":"Buprenorphine for the treatment of the neonatal abstinence syndrome","volume":"376","author":"Kraft","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0215","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJMc1709121","article-title":"Buprenorphine for the neonatal abstinence syndrome","volume":"377","author":"Christiansen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0220","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJMc1709121","article-title":"Buprenorphine for the neonatal abstinence syndrome","volume":"377","author":"Whalen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/cpt.1064","article-title":"The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome","volume":"103","author":"Moore","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijoa.2019.01.011_b0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ijoa.2019.01.011_b0235","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J Addict Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000542-200607000-00012","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"105","author":"van Dorp","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ijoa.2019.01.011_b0250","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","article-title":"Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials","volume":"120","author":"White","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ijoa.2019.01.011_b0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1213\/ANE.0000000000003477","article-title":"Opioid use disorders: Perioperative management of a special population","volume":"127","author":"Ward","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijoa.2019.01.011_b0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2006.01.022","article-title":"Reversibility of opioid receptor occupancy of buprenorphine in vivo","volume":"534","author":"Englberger","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0265","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","article-title":"Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study","volume":"23","author":"Zubieta","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0270","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ijoa.2019.01.011_b0280","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/ALN.0000000000001633","article-title":"To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine","volume":"126","author":"Anderson","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0285","first-page":"E1","article-title":"Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures","volume":"21","author":"Jonan","year":"2018","journal-title":"Pain Physician"},{"key":"10.1016\/j.ijoa.2019.01.011_b0290","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0295","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1360-0443.2012.03940.x","article-title":"Is sustained release natrexone an option for heroin-dependent pregnant women?","volume":"108","author":"Waal","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1360-0443.2012.03914.x","article-title":"Blocking endogenous opioids during development\u2013do we understand the consequences?","volume":"108","author":"White","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1360-0443.2012.03883.x","article-title":"Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?","volume":"108","author":"Stitzer","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0310","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1360-0443.2012.03865.x","article-title":"An ethical framework for conducting research on pregnant, opioid-dependent women","volume":"108","author":"McCullough","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/add.12071","article-title":"Naltrexone in the treatment of opioid-dependent pregnant women: common ground","volume":"108","author":"Jones","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0320","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1360-0443.2012.03811.x","article-title":"Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research","volume":"108","author":"Jones","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1360-0443.2012.04096.x","article-title":"Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research","volume":"108","author":"Clark","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ijoa.2019.01.011_b0330","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40265-017-0763-8","article-title":"A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijoa.2019.01.011_b0335","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s40265-017-0762-9","article-title":"A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijoa.2019.01.011_b0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ACO.0000000000000590","article-title":"The opioid epidemic and pregnancy: implications for anesthetic care","volume":"31","author":"Raymond","year":"2018","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0345","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpa.2017.01.003","article-title":"Postcesarean delivery analgesia","volume":"31","author":"Carvalho","year":"2017","journal-title":"Best Pract Res Clin Anesthesiol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0350","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.anclin.2016.09.010","article-title":"Optimal pain management after cesarean delivery","volume":"35","author":"Sutton","year":"2017","journal-title":"Anesthesiol Clin"},{"key":"10.1016\/j.ijoa.2019.01.011_b0355","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/AOG.0000000000002683","article-title":"Postpartum pain management","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0360","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/bfm.2018.29087.ejm","article-title":"ABM Clinical Protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother","volume":"3","author":"Martin","year":"2018","journal-title":"Breastfeed Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0890334416641909","article-title":"Breastfeeding among mothers on opioid maintenance treatment: a literature review","volume":"32","author":"Tsai","year":"2016","journal-title":"J Hum Lact"},{"key":"10.1016\/j.ijoa.2019.01.011_b0370","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10550490600626721","article-title":"Post-cesarean pain management of patients maintained on methadone or buprenorphine","volume":"15","author":"Jones","year":"2006","journal-title":"Am J Addict"},{"key":"10.1016\/j.ijoa.2019.01.011_b0375","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.AOG.0000275288.47258.e0","article-title":"Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy","volume":"110","author":"Meyer","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0380","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00952990902825413","article-title":"Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy","volume":"35","author":"Jones","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.ijoa.2019.01.011_b0385","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejpain.2010.03.002","article-title":"Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy","volume":"14","author":"Meyer","year":"2010","journal-title":"Eur J Pain"},{"key":"10.1016\/j.ijoa.2019.01.011_b0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jclinane.2010.09.013","article-title":"Postpartum analgesia with dexmedetomidine in opioid tolerance during pregnancy","volume":"23","author":"Wasiluk","year":"2011","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.ijoa.2019.01.011_b0395","first-page":"273","article-title":"Marked variability in peri-partum anesthetic management of patients on buprenorphine maintenance therapy (BMT): can there be an underlying acute opioid induced hyperalgesia precipitated by neuraxial opioids in BMT patients?","volume":"22","author":"Gupta","year":"2013","journal-title":"Middle East J Anaesthesiol"},{"key":"10.1016\/j.ijoa.2019.01.011_b0400","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1213\/ANE.0000000000002498","article-title":"Case series of successful postoperative pain management in buprenorphine maintenance therapy patients","volume":"125","author":"Leighton","year":"2017","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijoa.2019.01.011_b0405","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/ADM.0000000000000339","article-title":"Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine","volume":"11","author":"Vilkins","year":"2017","journal-title":"J Addict Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijoa.2018.01.001","article-title":"Use of epidural clonidine for the management of analgesia in the opioid addicted parturient on buprenorphine maintenance therapy: an observational study","volume":"34","author":"Hoyt","year":"2018","journal-title":"Int J Obstet Anesth"},{"key":"10.1016\/j.ijoa.2019.01.011_b0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12688\/f1000research.13350.1","article-title":"Management of eight labor and delivery patients dependent on buprenorphine (Subutex): a retrospective chart review","volume":"7","author":"Tith","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ijoa.2019.01.011_b0420","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/00000542-200412000-00019","article-title":"Combinations of bupivacaine, fentanyl, and clonidine for lumbar epidural postoperative analgesia: a novel optimization procedure","volume":"101","author":"Sveticic","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijoa.2019.01.011_b0425","first-page":"34","article-title":"Patient-controlled epidural analgesia in labor: the addition of clonidine to bupivacaine-fentanyl","volume":"25","author":"Paech","year":"2000","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.ijoa.2019.01.011_b0430","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijoa.2011.10.007","article-title":"Transversus abdominis plane catheters for post-cesarean delivery analgesia: a series of five cases","volume":"21","author":"Bollag","year":"2012","journal-title":"Int J Obstet Anesth"},{"key":"10.1016\/j.ijoa.2019.01.011_b0435","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1213\/ANE.0000000000002648","article-title":"The analgesic effect of ultrasound-guided quadratus lumborum block after cesarean delivery: a randomized clinical trial","volume":"126","author":"Krohg","year":"2018","journal-title":"Anesth Analg"}],"container-title":["International Journal of Obstetric Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959289X18300955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959289X18300955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:37:26Z","timestamp":1694615846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959289X18300955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":87,"alternative-id":["S0959289X18300955"],"URL":"https:\/\/doi.org\/10.1016\/j.ijoa.2019.01.011","relation":{},"ISSN":["0959-289X"],"issn-type":[{"value":"0959-289X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery","name":"articletitle","label":"Article Title"},{"value":"International Journal of Obstetric Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijoa.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}